Fennec Pharmaceuticals (FENC) Expected to Announce Quarterly Earnings on Thursday

Fennec Pharmaceuticals (NASDAQ:FENC) is projected to announce its earnings results before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of $0.02 per share and revenue of $16.42 million for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Fennec Pharmaceuticals Stock Up 4.0 %

FENC stock opened at $6.57 on Wednesday. Fennec Pharmaceuticals has a 52 week low of $3.96 and a 52 week high of $11.49. The company has a fifty day simple moving average of $6.41 and a two-hundred day simple moving average of $5.65. The firm has a market capitalization of $181.25 million, a P/E ratio of -65.69 and a beta of 0.36.

Analysts Set New Price Targets

Several equities analysts have commented on FENC shares. Wedbush reiterated an “outperform” rating and set a $13.00 price objective on shares of Fennec Pharmaceuticals in a research report on Monday, March 10th. HC Wainwright reiterated a “buy” rating and set a $13.00 price objective on shares of Fennec Pharmaceuticals in a research report on Tuesday, March 11th.

Insider Activity

In other news, Director Rosty Raykov sold 10,000 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $6.08, for a total value of $60,800.00. Following the sale, the director now owns 83,863 shares of the company’s stock, valued at approximately $509,887.04. This represents a 10.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last quarter, insiders have sold 31,186 shares of company stock valued at $203,389. 10.98% of the stock is currently owned by company insiders.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.